Article info

Protocol
Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis

Authors

  • Xuemei Xiang Basic Medical Laboratory, People’s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Yunming Li Department of Information, People’s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, ChinaDepartment of Statistics, Southwest Jiaotong University, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Xiaoguang Yang Department of Information, People’s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Wang Guo Department of Information, People’s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, ChinaDepartment of Statistics, Southwest Jiaotong University, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Pengfei Zhou Department of Information, People’s Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, ChinaSchool of Public Health, Southwest Medical University, Luzhou, Sichuan, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Yunming Li; lee3082{at}sina.com
View Full Text

Citation

Xiang X, Li Y, Yang X, et al
Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis

Publication history

  • Received October 26, 2021
  • Accepted July 6, 2022
  • First published August 4, 2022.
Online issue publication 
March 30, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.